Mayo Clinic physicians, genetic counselors, and allied health staff are in San Diego for the WORLDSymposium, which presents the latest information from basic science, translational research, and clinical trials for lysosomal diseases. If you are at the meeting, visit us at booth #23.
The U.S. Food and Drug Administration recently updated its electronic filing requirements for importing goods, including biological specimens. Full enforcement of the new requirements will begin on Thursday, February 9, at 6 a.m. EST.
Chromosome analysis, which was once the preferred genetic test for a wide variety of congenital abnormalities, is now one of the most frequently misordered cytogenetic tests at MML. This webinar will outline the differences in technologies and the appropriate use of each test.
Using targeted next-generation sequencing to identify lung tumors that may respond to targeted therapies by assessing somatic mutations simultaneously within EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2 and MET and identifying rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1.
The recommendations surrounding newborn screening are constantly in flux. Newly discovered treatments or emerging laboratory technologies are enabling additional recommendations for newborn screening.